Previous 10 | Next 10 |
BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer,...
2024-01-23 01:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-14 08:45:13 ET Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. ...
2024-01-12 09:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-05 13:00:18 ET More on ARK Innovation ETF: ARKK: Not The Beta Play One May Hope For ARKK: Forget About Innovation And Focus On What The U.S. Treasury Does ARKK Set To Ride This Bull Market Higher Into 2024 Cathie Wood's ARK Invest sold 759K shares of ...
2024-01-04 12:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting December 2023 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling...
BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer,...
2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...
2023-12-29 14:12:19 ET Summary The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have ...
2023-12-29 01:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...